Why the study?
Do novel flavagline derivatives provide cytotoxicity against cancer cells and cardio/neuroprotection in cell culture models?
Do novel flavagline derivatives provide cytotoxicity against cancer cells and cardio/neuroprotection in cell culture models?
Flavagline derivatives demonstrate potential as anticancer agents with concurrent cardioprotective and neuroprotective properties in preclinical models.
Flavaglines may reduce cisplatin neurotoxicity via optimized structures; leaves open clinical translation from animal data.
Flavaglines represent a family of plant natural products that display potent anticancer, cardioprotective, and neuroprotective activities. Novel flavagline derivatives were synthesized and examined for their cytotoxicity on a panel of human cancer cell lines, their cardioprotection against doxorubicin-induced apoptosis in cardiomyocytes, and their neuroprotection in culture models of Parkinson's disease and cisplatin-induced neurotoxicity. The structural requirements of flavaglines for cardio- and neuroprotection were for the first time unraveled and appeared to be slightly different from those for cytotoxicity on cancer cells. We provide also the first evidence that flavaglines may alleviate cisplatin-induced neurotoxicity, suggesting a prophylactic potential of these compounds to prevent this frequently encountered adverse effect of cancer chemotherapies.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: